Cathepsin S inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cathepsin S inhibitor The report assesses ...
January 2022
60 pages
CCR Inhibitor - Pipeline Insight, 2022
US$ 2,000.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CCR Inhibitor The report assesses the active CCR Inhibitor pipeline ...
January 2022
120 pages
CCR1 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CCR1 Inhibitor The report assesses the active CCR1 Inhibitor ...
January 2022
60 pages
CCR2 Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CCR2 Inhibitor The report assesses the active CCR2 Inhibitor ...
January 2022
90 pages
CCR3 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CCR3 Inhibitor The report assesses the active CCR3 Inhibitor ...
January 2022
60 pages
CCR4 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CCR4 Inhibitor The report assesses the active CCR4 Inhibitor ...
January 2022
60 pages
CCR5 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CCR5 Inhibitor The report assesses the active CCR5 Inhibitor ...
January 2022
60 pages
CD (Cluster of Differentiation) Inhibitor - Pipeline Insight, 2022
US$ 2,000.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CD (Cluster of Differentiation) Inhibitor The report ...
January 2022
120 pages
CD 19 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... 19 Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent ...
January 2022
60 pages
CD 3 Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... 3 Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent ...
January 2022
90 pages
CD 33 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... 33 Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent ...
January 2022
60 pages
CD 40 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... 40 Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent ...
January 2022
60 pages
CD152 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CD152 Inhibitor The report assesses the active CD152 Inhibitor ...
January 2022
60 pages
CD40 Agonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CD40 Agonist The report assesses the active CD40 Agonist pipeline ...
January 2022
60 pages
Cell Division Cycle 7 (CDC7) Related Protein Kinase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cell Division Cycle 7 (CDC7) Related Protein Kinase Inhibitor ...
January 2022
60 pages
Cell wall inhibitors - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cell Wall Synthesis Inhibitor The report assesses ...
January 2022
60 pages
cFMS Kinase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “cFMS Kinase Inhibitor The report assesses the active cFMS Kinase ...
January 2022
60 pages
Checkpoint Kinase Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Checkpoint Kinase Inhibitor The report assesses ...
January 2022
90 pages
Checkpoint Kinase 1 (Chk1) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Checkpoint Kinase 1 (Chk1) Inhibitor The report ...
January 2022
60 pages
Checkpoint Kinase 2 (Chk2) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Checkpoint Kinase 2 (Chk2) Inhibitor The report ...
January 2022
60 pages
Chemokine Receptor Antagonist - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Chemokine Receptor Antagonist The report assesses ...
January 2022
120 pages
Cholecystokinin Receptor (CCK) Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cholecystokinin Receptor (CCK) Antagonist The report ...
January 2022
60 pages
Cholesterol Absorption Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cholesterol Absorption Inhibitor The report ...
January 2022
60 pages
Cholesterylester Transfer Protein (CETP) Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cholesterylester Transfer Protein (CETP) Inhibitor The ...
January 2022
90 pages
CRF1 Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CRF1 Receptor Antagonist The report assesses ...
January 2022
60 pages
CXCR4 Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CXCR4 Inhibitor The report assesses the active CXCR4 Inhibitor ...
January 2022
90 pages
Cyclin-Dependent Kinase 1 (CDK1) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cyclin-Dependent Kinase 1 (CDK1) Inhibitor The report ...
January 2022
60 pages
Cyclin-Dependent Kinase 2 (CDK2) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cyclin-Dependent Kinase 2 (CDK2) Inhibitor The report ...
January 2022
60 pages
Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor The ...
January 2022
90 pages
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cyclin-Dependent Kinase 9 (CDK9) Inhibitor The report ...
January 2022
90 pages
Cyclophilin Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cyclophilin Inhibitor The report assesses ...
January 2022
60 pages
Cystic Fibrosis Transmembrane Conductance Regulators (CFTR) - Pipeline Insight, 2022
US$ 1,500.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cystic Fibrosis Transmembrane Conductance Regulators (CFTR) The ...
January 2022
90 pages
Cytochrome P450 Superfamily (CYP or CYP450) Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cytochrome P450 Superfamily (CYP or CYP450) Inhibitor The ...
January 2022
90 pages
Cytochrome P450 17 (CYP17) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cytochrome P450 17 (CYP17) Inhibitor The report ...
January 2022
60 pages
D Agonist - Pipeline Insight, 2022
US$ 2,000.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D Agonist The report assesses the active D Agonist pipeline ...
January 2022
120 pages
D Antagonist - Pipeline Insight, 2022
US$ 1,500.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D Antagonist The report assesses the active D Antagonist pipeline ...
January 2022
90 pages
D1 Agonist - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D1 Agonist The report assesses the active D1 Agonist pipeline ...
January 2022
60 pages
D1 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D1 Antagonist The report assesses the active D1 Antagonist pipeline ...
January 2022
60 pages
D2 Agonist - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D2 Agonist The report assesses the active D2 Agonist pipeline ...
January 2022
60 pages
D3 Agonist - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D3 Agonist The report assesses the active D3 Agonist pipeline ...
January 2022
60 pages
D3 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D3 Antagonist The report assesses the active D3 Antagonist pipeline ...
January 2022
60 pages
D4 Agonist - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D4 Agonist The report assesses the active D4 Agonist pipeline ...
January 2022
60 pages
D4 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “D4 Antagonist The report assesses the active D4 Antagonist pipeline ...
January 2022
60 pages
Delta Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Delta Antagonist The report assesses the active Delta Antagonist ...
January 2022
60 pages
Diglyceride Acyltransferase (DGAT) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Diglyceride Acyltransferase (DGAT) Inhibitor The report ...
January 2022
60 pages
Dihydroorotate dehydrogenase inhibitors - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Dihydroorotate Dehydrogenase (DHODH) Inhibitor The ...
January 2022
60 pages
DNA Methyltransferase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “DNA Methyltransferase Inhibitor The report assesses the active DNA ...
January 2022
60 pages
DNA-Dependent RNA Polymerase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “DNA-Dependent RNA Polymerase Inhibitor The report ...
January 2022
60 pages
Dopaminergic Agonist - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Dopaminergic Agonist The report assesses ...
January 2022
120 pages
